These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 1709658)

  • 1. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
    White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
    J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
    Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
    J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
    Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
    Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
    Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
    Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
    Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of vascularity in nodular melanoma and Spitz's nevus.
    Binder M; Steiner A; Mossbacher U; Hunegnaw M; Wolff K; Pehamberger H
    J Cutan Pathol; 1997 May; 24(5):272-7. PubMed ID: 9194579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigens associated with tumor progression in melanocytic neoplasia.
    Elder DE; Herlyn M
    Pigment Cell Res; 1992; Suppl 2():136-43. PubMed ID: 1409415
    [No Abstract]   [Full Text] [Related]  

  • 8. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
    Mehregan DR; Hamzavi I
    Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spitz's nevi with halo reaction: a histopathologic study of 17 cases.
    Harvell JD; Meehan SA; LeBoit PE
    J Cutan Pathol; 1997 Nov; 24(10):611-9. PubMed ID: 9449488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRAME Expression in Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
    Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical studies of conjunctival nevi and melanomas.
    Jakobiec FA; Bhat P; Colby KA
    Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The differential reactivity of cells of the melanocytic lineage with four monoclonal antibodies against IFN-gamma inducible molecules.
    Vacca A; Frassanito A; Rimoldi D; Dammacco F; Carrel S
    Anticancer Res; 1992; 12(1):1-9. PubMed ID: 1348919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunohistochemical analysis of ras gene expression in human melanomas and melanocytic nevi].
    Yasuda H
    Hokkaido Igaku Zasshi; 1989 May; 64(3):243-53. PubMed ID: 2670726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical demonstration of S-100 protein and melanoma-associated antigens in melanocytic nevi.
    Paul E; Cochran AJ; Wen DR
    J Cutan Pathol; 1988 Jun; 15(3):161-5. PubMed ID: 2456315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity.
    McNutt NS; Urmacher C; Hakimian J; Hoss DM; Lugo J
    J Cutan Pathol; 1995 Dec; 22(6):502-17. PubMed ID: 8835170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
    Nakanishi T; Hashimoto K
    Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
    Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
    Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
    Singh RS; Diwan AH; Zhang PS; Prieto VG
    J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen.
    Xu X; Azumi N; Skelton HG; Hearing VJ; Gersten DM
    Eur J Cancer; 1996 Jan; 32A(1):168-73. PubMed ID: 8695227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.